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liminating Triggers
f Ventricular Fibrillation
he Past, Present, and Future*
ruce D. Lindsay, MD
leveland, Ohio
he importance of ventricular ectopy and its causal rela-
ionship to induction of ventricular arrhythmias has been
ecognized for many years. The frequency and complexity of
entricular ectopy is related to risk, yet it is not an accurate
redictor of sustained ventricular arrhythmias for individual
atients. The practice of suppressing ventricular ectopy
uring the management of acute coronary syndromes has
een abandoned in the coronary care unit because treatment
ith antiarrhythmic medications has no survival benefit.
umerous trials were conducted to test the hypothesis that
uppression of ventricular ectopy by antiarrhythmic medi-
ations would improve survival. Josephson (1) correctly
redicted that attempts to suppress ventricular premature
eats (VPBs) with medication would fail to improve sur-
ival, and the results of the CAST (Cardiac Arrhythmia
uppression Trial) study (2) convincingly demonstrated the
utility of that strategy.
See page 522
The recent body of work refocuses attention on the
elationship between ventricular ectopy and recurrent ven-
ricular fibrillation (VF). In 2002, Haïssaguerre et al. (3)
eported the initial observation that VPBs arising from the
urkinje system had an important role in the induction of
diopathic VF. In 2003, they described the same approach
ith good results in a small number of patients with long
T syndrome or Brugada syndrome who had frequent
PBs and episodes of VF or polymorphic ventricular
achycardia (4). Later that year, Bansch et al. (5) reported 4
atients with combinations of repetitive VF, polymorphic
entricular tachycardia, or monomorphic ventricular tachy-
ardia who benefited from ablation of ventricular ectopy
hat arose from the Purkinje system. Similar results have
een reported by others (6) in a small series of patients or as
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.b
From Cardiac Electrophysiology and Pacing, Cleveland Clinic Foundation, Cleve-
and, Ohio.solated case reports, and Bogun et al. (7) demonstrated the
ole of Purkinje fibers in re-entrant ventricular tachycardia
fter myocardial infarction.
In this issue of the Journal, Knecht et al. (8) from
ordeaux provide long-term follow-up of patients with
diopathic VF who have undergone ablation of VPBs that
as presumed to have a causal relationship. In most cases,
he VPBs appeared to arise from the Purkinje system. As
iewed from the surface electrocardiogram, neither the
orphology of the VPBs nor the coupling interval was
nique. Most patients underwent ablation of more than one
rigin. The procedure diminished the risk of recurrent VF,
et late recurrence was observed, and some patients ap-
eared to benefit from treatment with antiarrhythmic med-
cations. Among patients with recurrent VF, some had
ecurrence of the original VPBs and others developed a new
ocus. Despite the clear benefit derived from ablation of
PBs, the fact that 18% experienced recurrent VF attests to
he need for an implantable cardioverter-defibrillator, and
he late recurrences at 3 to 5 years raise the possibility that
ith even longer follow-up the event rate may increase over
ime.
A practical consideration is that Knecht et al. (8) per-
ormed many of the ablations electively, and the time
equired was not exceptional compared with most ablation
rocedures. Nonetheless, the procedures are likely to be
ore prolonged in less-experienced centers. Although the
atients needed to have VPBs at the time of ablation or
ecordings of VPBs to compare with pace mapping, most of
he patients did not require emergency procedures. This
istinction is important because the logistic issues for
blation of VPBs in patients with VF “storm” are challeng-
ng. The schedule in busy laboratories is replete with other
ong elective procedures that cannot be interrupted or
eadily canceled and rescheduled. When protracted cases are
erformed in the middle of the night, they exact a toll on the
hysicians and supporting staff. Few electrophysiology lab-
ratories are equipped to deal with this challenge on a
outine basis.
Clinical electrophysiologists should not extend the results
f this study beyond its intended population. This is a select
roup of patients for whom the evidence was compelling
hat VPBs triggered VF. Although ablation of ventricular
ctopy can be of benefit in patients with recurrent VF, there
s no evidence that we should pre-emptively ablate ventric-
lar ectopy in patients who have not experienced sustained
entricular arrhythmias. To do so would lead us into the
ame line of reasoning that supported the CAST study.
Although the lack of benefit from treatment with anti-
rrhythmic medications may be related in part to the adverse
ffects of the drugs, it is likely that in most patients there
imply is no benefit from suppression of the ventricular
ctopy. Aggressive intervention by catheter ablation is
ssociated with certain risks that would outweigh the
enefits in most patients. Even among patients with struc-
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Eliminating Triggers of VF August 4, 2009:529–30ural heart disease who have survived isolated VF, ablation
f VPBs may not have the same impact as it does in patients
ith idiopathic VF or VF “storm.” The causal relation
etween VPBs and VF in these groups may not be appli-
able to all patients with VF.
Several laboratories have explored the role of Purkinje
bers in the initiation and maintenance of VF or polymor-
hic ventricular tachycardia. In 1998, Berenfeld and Jalife
9) used a 3-dimensional model to test the hypothesis that
e-entry involving the Purkinje muscle junction may be a
echanism of focal subendocardial activation. In addition
o the capacity for triggered activity, the differences between
urkinje fibers and myocardium in upstroke velocity, intra-
ellular coupling, and action potential duration may provide
he conditions for initiating or sustaining VF. Their model
upported the possibility that Purkinje fibers are involved in
he evolution and maintenance of re-entry with variable
urface electrocardiogram morphology that reflects changes
n epicardial activation.
Three studies from Dr. Idecker’s laboratory (10–12) at
he University of Alabama in Birmingham demonstrate the
otential role of the Purkinje system in VF. Dosdall et al.
10) showed that the Purkinje system is active during the
arly post-shock activation cycles, but further study is
equired to determine whether early activation initiates in
he Purkinje system as opposed to the myocardium. In a
econd study by Dosdall et al. (11), ablation of the Purkinje
ystem by Lugol solution hastened spontaneous VF termi-
ation and altered AF activation. Li et al. (12) recorded
lectrical activity of induced VF and found that over time
he incidence of re-entry in myocardium decreased but there
as an increased incidence of intramural foci. It is not clear
et whether these arise from Purkinje fibers.
Aside from the immediate benefit that ablation of VPBs
ffers to selected patients with VF, the work by Knecht et al.
8) and Bansch et al. (5) raise a number of important
uestions. Most center on why these patients are so prone to
F. Many patients with ventricular ectopy do not develop
F, so what makes the susceptible patients different? It
ppears that VPBs arising from the Purkinje system may be
articularly malignant, yet we do not know how many
eople who never experience VF have VPBs arising from
he Purkinje system. It may be more common than we
ppreciate. Perhaps there is something different about the
nterface between the Purkinje system and the myocardium
hat predisposes these individuals to micro–re-entry and the
nitiation of VF. One might speculate that tissue damage
ssociated with either ischemic or nonischemic cardiomy-
pathy would provide the substrate for this mechanism, but
hy does it occur in patients without any evidence of
tructural heart disease? Are there characteristic features
etected from the body surface that are unique identifiers of
isk? Can a noninvasive technology such as analysis of
K
y-wave alternans or electrocardiographic imaging shed
dditional light on why these patients are prone to VF?
hy does a patient with complex ectopy do well for months
r years and suddenly experience recurrent VF? What
hanged on that day? Is it the development of a different
PB origin that arises from the Purkinje system? Are there
utonomic or metabolic factors that we do not recognize?
Advances in medicine often raise more questions than
hey answer. I believe the observations from both clinical
nd basic science studies have important implications for the
ay we manage patients with recurrent VF, but even more
mportant is the interest they inspire and the insights we will
ain in future work to determine why patients develop VF
r why the ablation is so beneficial. The answers to these
uestions may extend our horizon and pave the way for new
trategies to prevent VF.
eprint requests and correspondence: Dr. Bruce D. Lindsay,
ection Head, Cardiac Electrophysiology and Pacing, Cleveland
linic Foundation, 9500 Euclid Avenue, J2-2, Cleveland, Ohio
4195. E-mail: lindsab@ccf.org.
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